Molecular basis for treating endometriosis with aromatase inhibitors
Molecular basis for treating endometriosis with aromatase inhibitors
复制标题
DOI：
10.1093/humupd/6.5.413
复制
发表时间：
2000-09-01
影响因子：
13.3
通讯作者：
Sasano, H
中科院分区：
文献类型：
--
作者：
Bulun, SE;Zeitoun, KM;Sasano, H
尽管芳香化酶抑制剂治疗绝经后子宫内膜异位症的一个异常积极的情况下，已经取得了显着的成功，需要大型临床试验，以确定是否芳香化酶抑制剂将有一个显着的作用，在子宫内膜异位症的医疗管理。将芳香化酶抑制剂引入子宫内膜异位症的治疗强调了基础研究的重要性，从而导致生殖疾病新策略的发展。早期研究表明芳香化酶活性在正常子宫内膜中检测不到，然而芳香化酶在子宫内膜异位症中表达不当，并被前列腺素E-2刺激。芳香化酶活性引起雌激素的局部生物合成，这反过来又刺激前列腺素E-2的产生，从而建立正反馈循环，这有利于雌激素和异黄酮在子宫内膜异位症中的积累，子宫内膜异位症是一种依赖雌激素生长的炎性疾病。
Although treatment of one unusually aggressive case of postmenopausal endometriosis with an aromatase inhibitor has been strikingly successful, large clinical trials are required to establish whether aromatase inhibitors will have a significant role in the medical management of endometriosis. Introduction of aromatase inhibitors into the treatment of endometriosis underscores the importance of basic research leading to the development of novel strategies in reproductive disorders. It was shown earlier that aromatase activity was not detectable in normal endometrium, Aromatase, however, is expressed inappropriately in endometriosis and stimulated by prostaglandin E-2. Aromatase activity gives rise to local biosynthesis of oestrogen, which, in turn, stimulates prostaglandin E-2 production, thus establishing a positive feedback cycle, This favours accumulation of oestrogen and prostaglandins in endometriosis, which is an inflammatory disorder dependent on oestrogen for growth.